Severe hepatitis caused by cyproterone acetate

J C Blake ¹, A M Sawyerr , J S Dooley

⁰Academic Department of Medicine, Royal Free Hospital School of Medicine, Hampstead, London.

Gut +

|

May 1, 1990

View abstract on PubMed

Summary

Cyproterone acetate, used for prostate cancer, can cause severe liver damage. Regular liver function tests are crucial for patients on high doses, with immediate drug cessation advised if abnormalities arise.

Area Of Science

Hepatology
Oncology
Pharmacology

Background

Cyproterone acetate is a widely used antiandrogen for treating prostate carcinoma.
Adverse hepatic reactions to cyproterone acetate are infrequently documented in medical literature.
The drug's potential for hepatotoxicity necessitates careful monitoring.

Observation

A case report details severe acute hepatitis in a 71-year-old male patient with prostatic carcinoma receiving cyproterone acetate.
This represents the fourth published instance of a significant adverse hepatic event linked to this medication.
The patient's presentation underscores the potential for serious liver injury.

Findings

The case substantiates existing, albeit limited, evidence of cyproterone acetate's hepatotoxic potential.
A strong association was observed between cyproterone acetate use and the development of acute hepatitis.
The severity of the hepatitis highlights the drug's risk profile.

Implications

Mandatory monitoring of liver function tests is recommended for patients on high-dose cyproterone acetate therapy.
Prompt discontinuation of the drug is advised upon detection of abnormal liver function test results.
This case emphasizes the need for increased vigilance regarding cyproterone acetate-induced liver injury in clinical practice.

Related Concept Videos